Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Targeted Daunorubicin Dosing to Overcome Chemotherapeutic Resistance in Children With Relapsed or Refractory Acute Leukemia

NCT04562792 is registered in ClinicalTrials.gov with Children's Mercy Hospital Kansas City as lead sponsor.

NCT NCT04562792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04562792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Targeted Daunorubicin Dosing to Overcome Chemotherapeutic Resistance in Children With Relapsed or Refractory Acute Leukemia
Lead sponsor
Children's Mercy Hospital Kansas City
Phase
Phase 2
Overall status
Completed
Start date
May 8, 2020
Completion date
June 30, 2022
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory acute lymphoblastic leukemia, refractory acute myeloid leukemia, relapsed pediatric all, relapsed pediatric aml